CCS
EXAS

Crosspoint Capital Strategies’s Exact Sciences EXAS Stock Holding History

Crosspoint Capital Strategies’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-85,984
Closed -$45.2M – 33
2017
Q4 		$45.2M Sell
85,984
-1,196
-1% -$63.9K 3.74% 8
2017
Q3 		$4.11M Sell
87,180
-16,669
-16% -$671K 3.18% 5
2017
Q2 		$3.67M Sell
103,849
-135,642
-57% -$4.19M 3.21% 6
2017
Q1 		$5.66M Sell
239,491
-3,224
-1% -$63.9K 4.75% 8
2016
Q4 		$3.24M Buy
+242,715
New +$3.92M 2.88% 24
2016
Q1 		– Sell
-325
Closed -$9K – 331
2015
Q4 		$9K Buy
+325
New +$3.02K ﹤0.01% 707
2015
Q3 		– Sell
-7,748
Closed -$230K – 790
2015
Q2 		$230K Buy
+7,748
New +$195K 0.07% 164
2015
Q1 		– Sell
-137,690
Closed -$3.78M – 579
2014
Q4 		$3.78M Buy
+137,690
New +$3.35M 1.32% 12

Other funds holding EXAS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Crosspoint Capital Strategies's EXAS Position: Q1 2018 in Review

Crosspoint Capital Strategies sold out of Exact Sciences (EXAS) in Q1 2018, closing a stake of 85,984 shares — an estimated $45.2M sold.

Crosspoint Capital Strategies first reported a position in EXAS in Q4 2014 and held it in 8 quarters. The position peaked at $45.2M in Q4 2017. 319 funds tracked by Wall St. Rank hold EXAS as of Q1 2018.

  • Crosspoint Capital Strategies reported no remaining Exact Sciences position as of Q1 2018 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 85,984 Exact Sciences shares in Q1 2018, an estimated $45.2M.
  • Crosspoint Capital Strategies first reported a position in Exact Sciences in Q4 2014 and held it in 8 quarters.
  • Crosspoint Capital Strategies's Exact Sciences position peaked at $45.2M in Q4 2017.
  • 319 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2018, filed 14 May 2018.